Cargando…

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

Background: Nivolumab and pembrolizumab, two PD1 inhibitors, trigger immune-related adverse events in approximately 50% of patients. Our objective was to determine whether these immune-related adverse events are associated with patient outcomes. Patients and Methods: Retrospective cohort study, real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959447/ https://www.ncbi.nlm.nih.gov/pubmed/32002292 http://dx.doi.org/10.1080/2162402X.2019.1682383

Ejemplares similares

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Bastacky, Melissa L., et al.
Publicado: (2021)

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
por: Dawidowska, Anna, et al.
Publicado: (2022)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma
por: Zhao, Jing-Jing, et al.
Publicado: (2020)

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study
por: Zheng, Xiaowei, et al.
Publicado: (2022)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
por: Huang, Guili, et al.
Publicado: (2022)

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
por: Chen, Xiaoling, et al.
Publicado: (2021)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

A Review of Immune-Mediated Adverse Events in Melanoma
por: Kennedy, Lucy Boyce, et al.
Publicado: (2019)

Complications and adverse events of plaque brachytherapy for ocular melanoma
por: Peddada, Krishi V., et al.
Publicado: (2019)

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach
por: Grimaud, Fabien, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer—an IMMUNOTARGET case series
por: Mushtaq, Rao, et al.
Publicado: (2022)

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
por: Goodman, Rachel S., et al.
Publicado: (2023)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
por: Sun, Fengze, et al.
Publicado: (2022)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma
por: Shreberk‐Hassidim, Rony, et al.
Publicado: (2022)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
por: Wu, Chiao-En, et al.
Publicado: (2020)

Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
por: Pourhassan, Hoda Z., et al.
Publicado: (2019)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
por: Engel-Nitz, Nicole M., et al.
Publicado: (2020)

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
por: Swami, Umang, et al.
Publicado: (2019)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
por: Liu, Wenhui, et al.
Publicado: (2021)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
por: Schaefer, Anne, et al.
Publicado: (2020)

Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda
por: Davies, Emma C., et al.
Publicado: (2012)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events
por: Fujisaki, Toshiya, et al.
Publicado: (2021)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV
por: Gay, Cynthia L., et al.
Publicado: (2021)

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
por: Abedian Kalkhoran, Hanieh, et al.
Publicado: (2023)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6denhfaftpavjg920had5d0pup